Özcan BÖR, Zeynep Canan ÖZDEMİR, Yeter Düzenli KAR

Çocuk hematoloji-onkoloji hastalarının febril nötropeni ataklarının değerlendirilmesi

Amaç: Febril nötropeni, kemoterapi alan hematoloji-onkoloji hastalarında hastalık ve ölümün en önemli nedenidir. Bu çalışmanın amacı maliniteli çocuk hastaların febril nötropeni ataklarının değerlendirilmesidir.Gereç ve Yöntemler: Malinite nedeni ile 2010 ve 2015 yılları arasında kemoterapi verilen 68 çocuk hastanın dosya bilgileri geriye dönük olarak incelendi. Hastaların demografik özellikleri, laboratuvar ölçümleri, enfeksiyon odakları ve kültürde üreyen mikroorganizmaların sıklığı incelendi. Ayrıca kemoterapi dönemlerine göre febril nötropenik atak sıklığı araştırıldı.Bulgular: İki yüz febril nötropenik atağın 81'inde (%40,5) klinik olarak tanımlanmış enfeksiyon odağı 73'ünde (%36,5) mikrobiyolojik olarak tanımlanmış enfeksiyon odağı vardı. Atakların 46'sında (%23) herhangi bir enfeksiyon odağı bulunamadı. Klinik olarak en sık görülen enfeksiyon odağı mukozit (%33,4) ve pnömoni (%24,7) idi. Mikrobiyolojik olarak tanımlanmış enfeksiyon ataklarının 55'inde (%75,3) kan kültüründe mikroorganizma izole edildi. Kan kültüründe en sık izole edilen etken gram negatif mikroorganizmalardı (%47,2). Mikrobiyolojik olarak tanımlanmış enfeksiyonlarda C-reaktif protein düzeyi klinik olarak tanımlanmış enfeksiyonlardan ve nedeni bilinmeyen ateş ataklarından yüksekti (p

Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients

Aim: Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The objective of this study was to evaluate febrile neutropenic episodes in children with malignancy.Material and Methods: Sixty-eight children who received chemotherapy for malignancy between 2010 and 2015 were retrospectively reviewed. The demographic characteristics, laboratory data, infection foci, and frequency of microorganisms grown in culture were examined. Also, the frequency of febrile neutropenic attacks was investigated according to the chemotherapy periods.Results: Of the total 200 episodes, 81 (40.5%) were clinically documented, and 73 (36.5%) were microbiologically documented infections. Fever of unknown origin was observed in 46 (23%) episodes. The most frequently clinically documented focus were mucositis (33.4%) and pneumonia (24.7%). Blood culture was positive in 55 (75.3%) episodes of microbiologically documented infections. The most commonly isolated microorganisms in blood culture were Gram-negative bacteria (47.2%). C-reactive protein levels in microbiologically documented infections were higher than in clinically documented infections, and fever of unknown origin (p

PDF

___

1. Crokaert F. Febrile neutropenia in children. Int J Antimicrob Agents 2000; 16: 173-6. [CrossRef ]
2. Basu SK, Fernandez ID, Fisher SG, Asselin B L, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005; 23: 7958-66. [CrossRef ]
3. Bakhshi S, Padmanjali KS, Arya LS. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. Pediatr Hematol Oncol 2008; 25: 385-92. [CrossRef ]
4. Baskaran ND, Gan GG, Adeeba K, Sam IC. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia. Int J Infect Dis 2007; 11: 513-17. [CrossRef ]
5. Blennow O, Ljungman P. The challenge of antibiotic resis¬tance in haematology patients. Br J Haematol 2016; 172: 497- 511. [CrossRef ]
6. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteremias among adult and pediatric haematology and cancer patients. J Infect 2014; 68: 321-31. [CrossRef ]
7. Ortega M, Marco F, Soriano A, et al. Epidemiology and outcome of bacteremia in neutropenic patients in a single institution from 1991-2012. Epidemiol Infect 2015; 143: 734-40. [CrossRef ]
8. Gudio C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013; 19: 474-9. [CrossRef ]
9. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011; 52: 56- 93. [CrossRef ]
10. Kebudi R, Devecioğlu Ö, Gürler N. Pediatrik febril nötropeni kılavuzu. Flora 2004; 9: 73-105.
11. Paul M, Gafter-Gvili A, Leibovici L, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Isr Med Assoc J 2007; 9: 424-9.
12. Klaassen IL, de Haas V, van Wijk JA, Kaspers GJ, Bijlsma M, Bökenkamp A. Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer 2011; 56: 868-70. [CrossRef ]
13. Clarke RT, Jenyon T, van Hamel Parsons V, King AJ. Neutropenic sepsis: management and complications. Clin Med 2013; 13: 185-7. [CrossRef ]
14. Aparicio J, Oltra A, Llorca C, et al. Randomized comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur J Cancer 1996; 32: 1739-43. [CrossRef ]
15. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45: 1296-304. [CrossRef ]
16. Sacar S, Hacioğlu SK, Keskin A, Turgut H. Evaluation of febrile neutropenic attacks in a tertiary care medical center in Turkey. J Infect Dev Ctries 2008; 2: 359-63. [CrossRef ]
17. Masmoudi S, Khanfir A, Maalej-Mezghan S, Hammami A, Frikha M. Chemotherapy-induced febrile neutropenia: About 186 episodes. Clinical, microbiological and therapeutic characteristics. Tunis Med 2015; 93: 217-22.
18. Afzal S, Ethier MC, Dupuis LL, et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 2009; 28: 1064-8. [CrossRef ]
19. Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 31: 623-9. [CrossRef ]
20. Jeddi R, Achour M, Amor RB, et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology 2010; 15: 28-32. [CrossRef ]
21. Güneş D, Mutafoğlu K, Çetinkaya H, Arslan H, Çakır D, Olgun N. Febrile neutropenic episodes in children with lymphoma and malignant solid tumors. J Pediatr Infect 2010; 4: 1-8.
22. Baysallar M, Üsküdar Güçlü A, Şenses Z, Kaptan K, Ataergin S, Başustaoğlu AC. Bacterial spectrum and antimicrobial susceptibility profile in blood cultures of patients with febrile neutropenia. Gulhane Med J 2007; 49: 168- 72.
23. Özdemir ZC, Koç A, Ayçiçek A. Microorganisms isolated from cultures and infection focus and antibiotic treatments in febrile neutropenic children from Şanlıurfa, Turkey. Turk J Pediatr 2016; 58: 47-53. [CrossRef ]
24. Kebudi R, Vural S, Gürler N, Anak S, (tüm katılan merkezler adına). Febril nötropenik kanserli çocuklarda klinik ve mikrobiyolojik kanıtlanmış infeksiyonlar ve infeksiyon etkenleri. İçinde: Kebudi R, Anak S, Vural S (editörler). Pediatrik hematoloji-onkoloji merkezlerinde febril nötropeni tanı ve tedavi uygulamaları, çalışmaları ve sonuç- ları kitabı. İstanbul: İstanbul Üniversitesi; 2004.p.100-5.
25. Akçay A, Türel Ö, Tuğcu D, et al. Bacteria isolated from pediatric hematology oncology clinic patients and their antibiotic susceptibility patterns. JOPP Derg 2011; 3: 68- 73.
26. Özdemir N, Tüysüz G, Çelik N, et al. Febrile neutropenia in children with acute lymphoblastic leukemia: single center experience. Turk Pediatri Ars 2016; 51: 79-86. [CrossRef ]
27. Tezcan G, Küpesiz A, Öztürk F, et al. Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey. Pediatr Hematol Oncol 2006; 23: 217-29. [CrossRef ]
28. Akova M, Akan H, Korten V, et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomized multicentre trial in patients without previous prophylactic antibiotics. meropenem study group of Turkey. Int J Antimicrob Agents 1999; 13: 15-9. [CrossRef ]
29. Yılmaz Ş, Ören H, Demircioğlu F, İrken G. Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols. Pediatr Hematol Oncol 2008; 25: 195-204. [CrossRef ]
30. Aslan S, Citak EC, Yis R, Değirmenci S, Arman D. Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey. Indian J Microbiol 2012; 52: 203-8. [CrossRef ]
31. Viscoli C, Castagnola E, Giacchino M, et al. Blood stream infections in children with cancer: a multicentre surveillance study of the Italian association of pediatric haematology and oncology. Supportive therapy group-infectious diseases section. Eur J Cancer 1999; 35: 770-4. [CrossRef ]
32. Sanboonrat P, Chainansamit S, Sriraska K. Febrile neutropenia in children with acute leukemia. Khon Kaen Med J 2009; 33: 2-8.
33. Meisner M, Tschaikowsky K, Schnabel S, Schmidt J, Katalinic A, Schüttler J. Procalcitonin-influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Clin Chem Clin Biochem 1997; 35: 597-601. [CrossRef ]
34. Fleischhack G, Cipic D, Juettner J, Hasan C, Bode U. Procalcitonin-a sensitive inflammation marker of febrile episodes in neutropenic children with cancer. Intensive Care Med 2000; 26: 202-11. [CrossRef ]
35. Chaudhary N, Kosaraju K, Bhat K, Bairy I, Borker A. Significance of interleukin-6 (IL-6) and C-reactive protein (CRP) in children and young adults with febrile neutropenia during chemotherapy for cancer: a prospective study. J Pediatr Hematol Oncol 2012; 34: 617-23. [CrossRef ]
36. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228-37. [CrossRef ]
37. Badr M, Hassan T, Sakr H, et al. Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences. Mol Clin Oncol 2016; 5: 300-6. [CrossRef ]
38. Lee JH, Kim SK, Han SB, et al. Increase in antibiotic resistant gram negative bacterial infections in febrile neutropenic children. Infect Chemother 2016; 48: 181-9.[CrossRef ]